Skip to main content
. 2011 Dec 27;153(2):985–994. doi: 10.1210/en.2011-1519

Fig. 2.

Fig. 2.

PLX4720 extends survival and reverses cachexia in orthotopic mice with human ATC. A, Mouse weight over time. B, Untreated mice developed weight loss, piloerection, and cachexia by 28 d. Vehicle-treated mice progressed to severe cachexia, whereas PLX4720-treated mice had reversal of weight loss, cachexia, and piloerection over the 3-wk course of therapy. *, P < 0.05.

HHS Vulnerability Disclosure